Royal Bank of Canada’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-59,200
| Closed | -$7.22M | – | 7749 |
|
|
2025
Q4 | $7.22M | Hold |
59,200
| – | – | ﹤0.01% | 2171 |
|
|
2025
Q3 | $5.93M | Sell |
59,200
-35,000
| -37% | -$3.15M | ﹤0.01% | 2537 |
|
|
2025
Q2 | $7.81M | Sell |
94,200
-5,000
| -5% | -$399K | ﹤0.01% | 2218 |
|
|
2025
Q1 | $8.04M | Sell |
99,200
-15,300
| -13% | -$1.37M | ﹤0.01% | 1911 |
|
|
2024
Q4 | $10.3M | Buy |
114,500
+30,300
| +36% | +$2.94M | ﹤0.01% | 1778 |
|
|
2024
Q3 | $8.32M | Sell |
84,200
-440,000
| -84% | -$43.2M | ﹤0.01% | 1899 |
|
|
2024
Q2 | $48.6M | Buy |
524,200
+115,000
| +28% | +$10.3M | 0.01% | 788 |
|
|
2024
Q1 | $38.8M | Buy |
409,200
+10,000
| +3% | +$928K | 0.01% | 885 |
|
|
2023
Q4 | $35.6M | Sell |
399,200
-190,800
| -32% | -$14.2M | 0.01% | 928 |
|
|
2023
Q3 | $43.1M | Buy |
590,000
+240,000
| +69% | +$19.2M | 0.01% | 768 |
|
|
2023
Q2 | $29.1M | Buy |
350,000
+75,000
| +27% | +$6.27M | 0.01% | 976 |
|
|
2023
Q1 | $21M | Buy |
+275,000
| New | +$22.8M | 0.01% | 1105 |
|
|
2021
Q1 | – | Sell |
-1,550,600
| Closed | -$218M | – | 7741 |
|
|
2020
Q4 | $218M | Hold |
1,550,600
| – | – | 0.06% | 262 |
|
|
2020
Q3 | $173M | Buy |
1,550,600
+30,000
| +2% | +$3.36M | 0.06% | 266 |
|
|
2020
Q2 | $170M | Buy |
1,520,600
+198,800
| +15% | +$19.6M | 0.07% | 239 |
|
|
2020
Q1 | $102M | Buy |
1,321,800
+50,000
| +4% | +$4.43M | 0.05% | 294 |
|
|
2019
Q4 | $121M | Hold |
1,271,800
| – | – | 0.04% | 354 |
|
|
2019
Q3 | $97M | Hold |
1,271,800
| – | – | 0.04% | 376 |
|
|
2019
Q2 | $112M | Buy |
1,271,800
+31,100
| +3% | +$2.65M | 0.04% | 333 |
|
|
2019
Q1 | $112M | Buy |
1,240,700
+831,400
| +203% | +$70.7M | 0.05% | 317 |
|
|
2018
Q4 | $29.4M | Buy |
409,300
+25,000
| +7% | +$2.01M | 0.01% | 770 |
|
|
2018
Q3 | $36.8M | Sell |
384,300
-95,700
| -20% | -$9.28M | 0.02% | 747 |
|
|
2018
Q2 | $45.7M | Buy |
480,000
+140,000
| +41% | +$12.9M | 0.02% | 601 |
|
|
2018
Q1 | $29.8M | Sell |
340,000
-56,500
| -14% | -$5.16M | 0.01% | 843 |
|
|
2017
Q4 | $33.7M | Hold |
396,500
| – | – | 0.01% | 814 |
|
|
2017
Q3 | $34.3M | Buy |
396,500
+56,500
| +17% | +$4.53M | 0.02% | 755 |
|
|
2017
Q2 | $26.2M | Sell |
340,000
-30,000
| -8% | -$2.13M | 0.01% | 881 |
|
|
2017
Q1 | $25.7M | Buy |
370,000
+330,000
| +825% | +$22.2M | 0.01% | 872 |
|
|
2016
Q4 | $2.37M | Sell |
40,000
-128,200
| -76% | -$7.91M | ﹤0.01% | 2459 |
|
|
2016
Q3 | $11.2M | Buy |
168,200
+28,200
| +20% | +$1.74M | 0.01% | 1405 |
|
|
2016
Q2 | $7.57M | Hold |
140,000
| – | – | ﹤0.01% | 1634 |
|
|
2016
Q1 | $7.23M | Hold |
140,000
| – | – | ﹤0.01% | 1575 |
|
|
2015
Q4 | $9.83M | Sell |
140,000
-169,300
| -55% | -$11.5M | 0.01% | 1435 |
|
|
2015
Q3 | $19.3M | Buy |
309,300
+153,300
| +98% | +$12.1M | 0.01% | 790 |
|
|
2015
Q2 | $13.1M | Buy |
+156,000
| New | +$12.1M | 0.01% | 1072 |
|
Other funds holding XBI
Royal Bank of Canada's XBI Position: Q1 2026 in Review
Royal Bank of Canada increased its State Street SPDR S&P Biotech ETF (XBI) stake by 3.8% in Q1 2026, buying an estimated $2.3M and bringing the position to 510,065 shares worth $65.2M. The position accounts for 0.01% of the portfolio, ranked #800.
Royal Bank of Canada first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $102M in Q1 2024. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Royal Bank of Canada held 510,065 shares of State Street SPDR S&P Biotech ETF worth $65.2M as of Q1 2026.
- Royal Bank of Canada bought 18,452 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $2.3M.
- State Street SPDR S&P Biotech ETF made up 0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #800 holding.
- Royal Bank of Canada first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
- Royal Bank of Canada's State Street SPDR S&P Biotech ETF position peaked at $102M in Q1 2024.
- 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.